Anastasiia Obozina

Ms. Anastasiia Obozina

Moscow Institute of Physics and Technology, Dolgoprudnyy, Moskovskaya Oblast’, Russia
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AOAnastasiia Obozina
Anastasiia Obozina
EKElena Komedchikova
Elena Komedchikova
OKOlga Kolesnikova
Olga Kolesnikova
AIAnna Iureva
Anna Iureva
VKVera Kovalenko
Vera Kovalenko
VSVictoria Shipunova
Victoria Shipunova
Targeted nanoparticles of different origins are considered as new-generation diagnostic and therapeutic tools. However, there are no targeted drug formulations within the composition of nanoparticles approved by the FDA for use in the clinic, which is associated with the insufficient effectiveness of the developed candidates, the difficulties of their biotechnological production, and inadequate batch-to-batch reproducibility. Targeted protein self-assembling nanoparticles circumvent this problem since proteins are encoded in DNA and the final protein product is produced in only one possible way. We believe that the combination of the endless biomedical potential of protein carriers as nanoparticles and the standardized protein purification protocols will make significant progress in “magic bullet” creation possible, bringing modern biomedicine to a new level. In this review, we are focused on the currently existing platforms for targeted self-assembling protein nanoparticles based on transferrin, lactoferrin, casein, lumazine synthase, albumin, ferritin, and encapsulin proteins, as well as on proteins from magnetosomes and virus-like particles. The applications of these self-assembling proteins for targeted delivery in vitro and in vivo are thoroughly discussed, including bioimaging applications and different therapeutic approaches, such as chemotherapy, gene delivery, and photodynamic and photothermal therapy. A critical assessment of these protein platforms’ efficacy in biomedicine is provided and possible problems associated with their further development are described.

11 December 2025 in Biosensors
Verified
Journal Article
Open access
PDF file
OKOlga Kolesnikova
Olga Kolesnikova
DSDmitry Shikvin
Dmitry Shikvin
AAArina Antonova
Arina Antonova
AIAnna Iureva
Anna Iureva
EKElena Komedchikova
Elena Komedchikova
VSVictoria Shipunova
Victoria Shipunova
Background/Objectives: Nanoparticles have emerged as indispensable tools in modern biomedicine, enabling precise diagnostics, targeted therapy, and controlled drug delivery. Despite their rapid progress, the translation of nanoparticle-based systems critically depends on the ability to detect, quantify, and track them across complex biological environments. Over the past two decades, a wide spectrum of detection modalities has been developed, encompassing optical, magnetic, acoustic, nuclear, cytometric, and mass spectrometric principles. Yet, no comprehensive framework has been established to compare these methods in terms of sensitivity, spatial resolution, and clinical applicability. Methods: Here we show a systematic analysis of all broadly applicable nanoparticle detection strategies, outlining their mechanisms, advantages, and drawbacks, and providing illustrative examples of practical applications. Results: This comparison reveals that each modality occupies a distinct niche: optical methods offer high sensitivity but limited penetration depth; magnetic and acoustic modalities enable repeated non-invasive tracking; nuclear imaging ensures quantitative, whole-body visualization; and invasive biochemical or histological assays achieve ultimate detection limits at the cost of tissue integrity. These findings redefine how each technique contributes to nanoparticle biodistribution and mechanistic studies, clarifying which are best suited for translational and clinical use. Conclusions: Placed in a broader context, this review bridges fundamental nanotechnology with biomedical applications, outlining a unified methodological framework that will guide the rational design, validation, and clinical implementation of nanoparticle-based therapeutics and diagnostics. By synthesizing the field into a single comparative framework, it also provides an accessible entry point for newcomers in nanotechnology and related biomedical sciences.

5 July 2024 in Heliyon
Verified
Journal Article
Open access
OKOlga A. Kolesnikova
Olga A. Kolesnikova
EKElena Komedchikova
Elena Komedchikova
SZSvetlana D. Zvereva
Svetlana D. Zvereva
AOAnastasiia Obozina
Anastasiia Obozina
ODOlha V. Dorozh
Olha V. Dorozh
VSVictoria Shipunova
Victoria Shipunova
Cancer is unquestionably a global healthcare challenge, spurring the exporation of novel treatment approaches. In recent years, nanomaterials have garnered significant interest with the greatest hopes for targeted nanoformulations due to their cell-specific delivery, improved therapeutic efficacy, and reduced systemic toxicity for the organism. The problem of successful clinical translation of nanoparticles may be related to the fact that most in vitro tests are performed at pH values of normal cells and tissues, ranging from 7.2 to 7.4. The extracellular pH values of tumors are characterized by a shift to a more acidic region in the range of 5.6–7.0 and represent a crucial target for enhancing nanoparticle delivery to cancer cells. Here we show the method of non-active protein incorporation into the surface of HER2-targeted nanoparticles to achieve optimal cellular uptake within the pH range of the tumor microenvironment. The method efficacy was confirmed in vitro and in vivo showing the maximum binding of nanoparticles to cells at a pH value 6.4. Namely, fluorescent magnetic nanoparticles, modified with HER2-recognising affibody ZHER2:342, with proven specificity in terms of HER2 recognition (with 62-fold higher cellular uptake compared to control nanoparticles) were designed for targeting cancer cells at slightly acidic pH values. The stabilizing protein, namely, bovine serum albumin, one of the major blood components with widespread availability and biocompatibility, was used for the decoration of the nanoparticle surface to alter the pH response of the targeting magnetic conjugates. The optimally designed nanoparticles showed a bell-shaped dependency of interaction with cancer cells in the pH range of 5.6–8.0 with maximum cellular uptake at pH value 6.4 close to that of the tumor microenvironment. In vivo experiments revealed that after i.v. administration, BSA-decorated nanoparticles exhibited 2 times higher accumulation in tumors compared to magnetic nanoparticles modified with affibody only. Thus, we demonstrated a valid method for enhancing the specificity of targeted nanoparticle delivery to cancer cells without changing the functional components of nanoparticles.

26 November 2025 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
AOAnastasiia Obozina
Anastasiia Obozina
AGAlexander Gopanenko
Alexander Gopanenko
SZSvetlana D. Zvereva
Svetlana D. Zvereva
KOKonstantin Okonechnikov
Konstantin Okonechnikov
VSVictoria Shipunova
Victoria Shipunova

22 December 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
AOAnastasiia Obozina
Anastasiia Obozina
APA.A. Pakhomov
A.A. Pakhomov
AFA. Yu Frolova
A. Yu Frolova
SDSergey Deyev
Sergey Deyev
VSVictoria Shipunova
Victoria Shipunova

1 May 2025 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
EKElena Komedchikova
Elena Komedchikova
OKOlga A. Kolesnikova
Olga A. Kolesnikova
AOAnastasiia Obozina
Anastasiia Obozina
AAArina O. Antonova
Arina O. Antonova
ADAlexei M. Dukat
Alexei M. Dukat
VSVictoria Shipunova
Victoria Shipunova